Technology Transfer: EU Challenges and StrategiesVideo Youtube скачать в хорошем качестве

Technology Transfer: EU Challenges and StrategiesVideo Youtube

In this episode of IoT & IP Explained, I speak with Timo Minssen, Professor of Law at the University of Copenhagen and Founding Director of the Centre for Advanced Studies in Bioscience Innovation Law. We explore why Europe excels at research but still struggles to turn knowledge into scalable, real-world impact. The conversation looks at technology transfer not as a back-office function, but as core innovation infrastructure. We discuss why patents alone are no longer enough, how IP, data, and know-how increasingly form bundled assets, and what this means for universities, startups, and established companies. We also touch on risk culture in Europe, regulatory fragmentation, competition law, standardisation, data access, AI in tech transfer, and the growing importance of innovation ecosystems and innovation districts. Timo Minssen holds the UNESCO Co-Chair in the Right to Science. He is an Inter-CeBIL Research Affiliate at Harvard Law School and the University of Cambridge, and an Associate Member of McGill University’s Centre of Genomics and Policy. His research and practice focus on IP, competition, and regulatory law for health and life-science technologies, including AI, quantum technologies, advanced medical technologies, and biotechnology. He holds a German law degree (University of Göttingen) and graduate degrees (LL.M., M.I.C.L., LL.Lic., LL.D.) from Lund and Uppsala Universities. He trained in the German court system, at the European Patent Office, and in law firms and start-ups. He has held visiting positions at, among others, the Technical University of Munich, the Universities of Cambridge and Oxford, Waseda Law School, Harvard Law School, and the Max Planck Institute for Innovation and Competition, and previously taught comparative European and US patent law at Chicago-Kent College of Law. Minssen serves on the Scientific Advisory Board of the Munich Intellectual Property Law Centre (MIPLC) and advises the WHO, WIPO, the European Commission, companies, national governments, and law firms. At UCPH he leads interdisciplinary projects on precision medicine, AI-assisted surgery, medical devices and ATMPs, antimicrobial resistance, pandemic preparedness, advanced medical computing, and sustainable innovation. He is PI of a major Novo Nordisk Foundation–funded bioscience innovation law program with partners including Harvard, DTU, and the Universities of Cambridge and Michigan. He has authored 8 books and 240+ publications and is frequently featured in international media.